101079-63-4

Basic information

• Product Name: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE
• Synonyms: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE;3,4-Diamino-2,6-dichloropyridine;2,6-Dichloro-3,4-pyridinediamine;6-dichloropyridine-3;6-dichloro-3,4-pyridinediaMine;3,4-PyridinediaMine, 2,6-dichloro-;2,6-DICHLOROPYRIDINE-3,4-DIAM
• CAS NO: 101079-63-4
• Molecular Formula: C5H5Cl2N3
• Molecular Weight: 178.02
• Product Categories: Heterocycle-Pyridine series
• Mol File: 101079-63-4.mol
• Article Data: 20

Chemical Properties

• Melting Point: 181-183℃
• Boiling Point: 424.014 °C at 760 mmHg
• Flash Point: 210.236 °C
• Appearance: /
• Density: 1.602 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.693
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 0.50±0.50(Predicted)
• CAS DataBase Reference: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(101079-63-4)
• EPA Substance Registry System: 2,6-DICHLOROPYRIDINE-3,4-DIAMINE(101079-63-4)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 101079-63-4(Hazardous Substances Data)

Usage

General Description

2,6-Dichloropyridine-3,4-diamine is an organic compound and a derivative of pyridine, characterized by two chlorine atoms and two amine groups attached to its heterocyclic ring. 2,6-DICHLOROPYRIDINE-3,4-DIAMINE is known for its reactivity and ability to undergo several types of reactions, primarily due to the presence of multiple functional groups. As such it can often be used as a building block in chemical synthesis. It's often involved in pharmaceutical and agricultural compounds production. However, like many other chemicals in this group, it may have potential health and environmental hazards that need to be fully assessed before extensive use.

InChI:InChI=1/C5H5Cl2N3/c6-3-1-2(8)4(9)5(7)10-3/h1H,9H2,(H2,8,10)

Upstream product

• 25194-01-8 4-nitro-2,6-dichloro-pyridine 
• 2587-03-3 2,6-dichloro-N-nitro-4-pyridinamine 
• 2587-00-0 2,6-dichloropyridine N-oxide 
• 2587-02-2 2,6-dichloro-[4]pyridylamine 
• 2402-78-0 2,6-dichloropyridine 
• 668268-66-4 3-amino-4-acetamido-2,6-dichloropyridine 
• 2897-43-0 2,6-dichloro-3-nitropyridin-4-amine 

Downstream Products

• 668268-64-2 8-chloro-3-deazaadenine 
• 668268-69-7 3-chloro-3-deazaadenine 
• 668268-68-6 2,6-dichloro-8-oxo-3-deazaadenine 
• 6811-77-4 3-deazaadenine 
• 52559-17-8 2-chloro-3-deazaadenine 
• 168123-76-0 5,7-dichloro-6-aza-1,4-dihydroquinoxaline-2,3-dione 
• 2589-12-0 4,6-dichloro-3H-imidazo[4,5-c]pyridine 

Relevant articles and documents

Discovery of the S1P2 Antagonist GLPG2938 (1-[2-Ethoxy-6-(trifluoromethyl)-4-pyridyl]-3-[[5-methyl-6-[1-methyl-3-(trifluoromethyl)pyrazol-4-yl]pyridazin-3-yl]methyl]urea), a Preclinical Candidate for the Treatment of Idiopathic Pulmonary Fibrosis

Mounting evidence from the literature suggests that blocking S1P2 receptor (S1PR2) signaling could be effective for the treatment of idiopathic pulmonary fibrosis (IPF). However, only a few antagonists have been so far disclosed. A chemical enablement strategy led to the discovery of a pyridine series with good antagonist activity. A pyridazine series with improved lipophilic efficiency and with no CYP inhibition liability was identified by scaffold hopping. Further optimization led to the discovery of 40 (GLPG2938), a compound with exquisite potency on a phenotypic IL8 release assay, good pharmacokinetics, and good activity in a bleomycin-induced model of pulmonary fibrosis.

Discovery of 6-[(3 S,4 S)-4-Amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-3-(2,3-dichlorophenyl)-2-methyl-3,4-dihydropyrimidin-4-one (IACS-15414), a Potent and Orally Bioavailable SHP2 Inhibitor

Src homology 2 (SH2) domain-containing phosphatase 2 (SHP2) plays a role in receptor tyrosine kinase (RTK), neurofibromin-1 (NF-1), and Kirsten rat sarcoma virus (KRAS) mutant-driven cancers, as well as in RTK-mediated resistance, making the identification of small-molecule therapeutics that interfere with its function of high interest. Our quest to identify potent, orally bioavailable, and safe SHP2 inhibitors led to the discovery of a promising series of pyrazolopyrimidinones that displayed excellent potency but had a suboptimal in vivo pharmacokinetic (PK) profile. Hypothesis-driven scaffold optimization led us to a series of pyrazolopyrazines with excellent PK properties across species but a narrow human Ether-à-go-go-Related Gene (hERG) window. Subsequent optimization of properties led to the discovery of the pyrimidinone series, in which multiple members possessed excellent potency, optimal in vivo PK across species, and no off-target activities including no hERG liability up to 100 μM. Importantly, compound 30 (IACS-15414) potently suppressed the mitogen-activated protein kinase (MAPK) pathway signaling and tumor growth in RTK-activated and KRASmut xenograft models in vivo.

CDK INHIBITORS

Provided is a compound represented by structural formula (I), or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.